|
|

Title: Methods of preventing or treating allergies
United States Patent: 6,506,380
Issued: January 14, 2003
Inventors: Isolauri; Erika (Raisio, FI); Metsaniitty; Leena
(Helsinki, FI); Korhonen; Hannu (Riihimaki, FI); Salminen; Seppo (Turku, FI);
Syvaoja; Eeva-Liisa (Espoo, FI)
Assignee: Valio Oy (Helsinki, FI)
Appl. No.: 973963
Filed: May 29, 1998
PCT Filed: January 3, 1997
PCT NO: PCT/FI96/00350
371 Date: June 12, 1996
Abstract
The present invention provides method of making a protein hydrolysate
formula and protein hydrolysate formulas made thereby for downregulating
hypersensitivity and for promoting gut immune barrier, and methods of
preventing or treating allergies, especially cow's milk allergy by combining
the protein with probiotic gastrointestinal bacteria, especially
Lactobacilli. The probiotics make it possible to influence the immunological
balance, whereby allergy can be prevented by affecting the initiation
mechanism of allergy. The present invention makes it possible to develop a
person's tolerance of proteins by actively promoting a tolerogenic immune
response. In addition, present invention provides for administering
fragments of an allergen modified by probiotic gastrointestinal bacteria in
order to desensitize a immune response to systemic hyporesponsiveness.
SUMMARY OF THE INVENTION
The present inventors have now found that certain bacteria of the
gastrointestinal tract, especially Lactobacilli, and especially bacteria
having probiotic characteristics, can be used to enhance the efficacy of
elimination diets and to improve the oral tolerance, in preventing or
treating food-induced hypersensitivity reactions in a patient.
One aspect of the invention is that protein hydrolysates obtained by
hydrolysis of proteins with above mentioned gastrointestinal bacteria can
also be used to said purpose. We show here that protein hydrolysates
obtained according to this invention have an immunological effect promoting
hypoallergenicity. The hydrolysates downregulate hypersensitivity reactions
thus promoting the gut immune barrier function, i.e. stabilising the gut
mucosal barrier.
The present invention provides an improved protein hydrolysate formula
downregulating hypersensitivity reactions and promoting the gut immune
barrier function. The hydrolysate formula is obtainable by hydrolysing
proteins with enzymes obtained from probiotic gastrointestinal bacteria,
especially Lactobacilli, which have adhesive and colonizing characteristics
and a protease enzyme system which are similar to those of the strain
Lactobacillus GG (ATCC 53103), and with trypsin and/or pepsin.
Alternatively, a protein hydrolysate formula of the invention can be
obtained by hydrolysing proteins with trypsin and/or pepsin, and adding to
the hydrolysate so obtained a bacterial preparation comprising probiotic
gastrointestinal bacteria, especially Lactobacilli, which have adhesive and
colonizing characteristics and a protease enzyme system which are similar to
those of the strain Lactobacillus GG (ATCC 53103). The bacteria are added
into the hydrolysate formula preferably as a lyophilized preparation.
While administering such a hydrolysate formula to a patient, it is to be
expected that the hydrolysing enzymes of the bacteria present are released
in vivo whereby the same effect is achieved as with an improved hydrolysate
formula as defined above. In addition, the viable bacteria stabilize the gut
mucosal barrier enhancing the local defence.
An embodiment of this invention is a method of preventing or treating
food-induced hypersensitivity reactions in an infant, which method comprises
the step of administering to an infant at risk the improved protein
hydrolysate formula of the invention, or alternatively a protein hydrolysate
formula together with a bacterial preparation comprising probiotic
gastrointestinal bacteria, especially Lactobacilli, which have adhesive and
colonizing characteristics and a protease enzyme system which are similar to
those of the strain Lactobacillus GG (ATCC 53103).
A further embodiment of this invention is a method of treating cow's milk
allergy in a patient, comprising administering to the patient the improved
protein hydrolysate formula of the invention or, alternatively administering
a protein hydrolysate formula together with a bacterial preparation
comprising probiotic gastrointestinal bacteria, especially Lactobacilli,
which have adhesive and colonizing characteristics and a protease enzyme
system which are similar to those of the strain Lactobacillus GG (ATCC
53103).
The invention also provides a method of promoting tolerogenic immune
responses to food antigens in a patient, comprising oral administration of
the improved protein hydrolysate formula of the invention to the patient,
or, alternatively, a bacterial preparation comprising probiotic
gastrointestinal bacteria, especially Lactobacilli, which have adhesive and
colonizing characteristics and a protease enzyme system which are similar to
those of the strain Lactobacillus GG (ATCC 53103), or, alternatively, a
protein hydrolysate formula together with a bacterial preparation comprising
probiotic gastrointestinal bacteria, especially Lactobacilli, which have
adhesive and colonizing characteristics and a protease enzyme system which
are similar to those of the strain Lactobacillus GG (ATCC 53103).
In the methods of the invention as defined above, when a protein hydrolysate
formula is used in combination with selected probiotic bacteria as defined
above, such a formula can be any suitable protein hydrolysate formula, known
or novel. It can thus be either a partial protein hydrolysate, or
alternatively an extensively hydrolysed formula. Preparation of a protein
hydrolysate suitable for this purpose is disclosed e.g. in EP patent
application No. 601 802.
Preferred bacterium to be used in the formulae and methods of the invention
is Lactobacillus GG (ATCC 53103).
In this specification and in the appended claims the phrase "bacteria,
especially Lactobacilli, which have adhesive and colonizing characteristics
and a protease enzyme system which are similar to those of the strain
Lactobacillus GG (ATCC 53103)" should be understood to define bacteria whose
adhesive and colonizing characteristics are comparable to those of the LGG
strain, e.g. as defined in EP-patent 199 535. These bacteria are also
supposed to have same kind of enzyme system as LGG, which means that enzymes
derived from such bacteria are able to degrade proteins to produce
hydrolysation products with same effects as those obtained using enzymes
derived from LGG.
Abbreviations
CI confidence interval
IFN-.gamma. Interferon-.gamma.
IgA Immunoglobulin A
IgE Immunoglobulin E
IL-4 Interleukin-4
LGG Lactobacillus GG (ATCC 53103)
OKT3 anti-CD3 antibody
PBMC peripheral blood mononuclear cells
TNF-.alpha. tumour necrosis factor .alpha.
WF test group receiving extensively hydrolysed Whey
Formula
WF-GG test group receiving extensively hydrolysed Whey
Formula and LGG preparation
P/T-casein = casein hydrolysed by pepsin and trypsin
P/T-.alpha.s1 -casein = .alpha.s1 -casein hydrolysed by pepsin
and trypsin
Claim 1 of 13 Claims
What is claimed is:
1. A method of making a hypoallergenic protein hydrolysate formula to be
administered to a patient for downregulating hypersensitivity reactions and
for promoting gut immune barrier in said patient, comprising:
hydrolysing proteins with enzymes obtained from a bacterial preparation
comprising Lactobacillus GG (ATCC 53103) and with pepsin and/or trypsin,
wherein the protein hydrolysate formula has an immunological effect that
promotes hypoallergenicity when administered to said patient.
____________________________________________
If you want to learn more
about this patent, please go directly to the U.S.
Patent and Trademark Office Web site to access the full
patent.
|